Dogwood Therapeutics (DWTX) Q4 Loss Narrows to $0.26, Beats Estimates
Dogwood Therapeutics posts Q4 loss of $0.26/share, 69.8% narrower than the $0.86 consensus, as clinical-stage biotech reduces burn rate.
ADVERTISEMENT
Earnings
General Mills (GIS) Q3 EPS Misses by 12% at $0.64 as Revenue Falls 8% YoY to $4.44B
General Mills Q3 EPS of $0.64 missed estimates by 12.1% as strategic pricing investments weighed on results; management reaffirms guidance,…
Star Equity Holdings Slips to a Loss in Q4 FY25; Revenue Surges 69% to $56.8M
Star Equity posts Q4 loss of $0.10 per share, missing estimates by 152.6%, despite 69% revenue growth to $56.8M.
Ovid Therapeutics (OVID) Swings to $0.06 EPS in Q4 FY25
Ovid Therapeutics swings to $0.06 EPS profit versus -$0.10 estimate, reversing year-ago loss with $9.7M net income on $700K revenue.
Weibo Corporation (WB) Misses Q4 EPS Estimates
Weibo Corporation (WB) delivered Q4 2025 adjusted earnings of $0.25 per share, below analysts' $0.32 forecast (miss by 20.8%).
Trevi Therapeutics (TRVI) Q4 Loss Narrows to $0.06/Share vs $0.10 Estimate, 37% Better Than Expected
Trevi Therapeutics narrows Q4 loss to $0.06 per share, beating estimates by 37% as the pre-revenue biotech maintains unanimous analyst…
Solaris Energy Infrastructure: 2025 Performance Report
Solaris Energy Infrastructure beats adjusted EPS estimates by 41.5% but misses on revenue as capital spending drives negative free cash…
Kestra Medical (KMTS) Revenue Surges 62.7% YoY to $24.6M; Loss Narrows
Kestra Medical posted a slightly wider-than-expected Q3 loss of $0.61/share, but revenue surged 63% year-over-year to top estimates.
HealthEquity (HQY) Q4 EPS Plunges 42.6% YoY to $0.95, Misses Estimates Despite $334.6M Revenue Beat
HealthEquity's Q4 GAAP EPS of $0.58 missed estimates by 35.4% despite revenue topping consensus, with fiscal 2027 guidance now in…
Titan America (TTAM) Q4 EPS Beats by 6.7% at $0.24, Revenue Rises 4.1% to $405.7M
Titan America's Q4 EPS of $0.26 beat estimates by 6.7%, though revenue of $405.7M missed consensus as margin expansion offset…